Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2004 Jun;79(5):411-9.
doi: 10.1532/ijh97.04054.

Imatinib mesylate in the treatment of chronic myelogenous leukemia

Gautam Borthakur  1 , Jorge E Cortes
Affiliations
Review

Imatinib mesylate in the treatment of chronic myelogenous leukemia

Gautam Borthakur et al. Int J Hematol. 2004 Jun.

Abstract

Imatinib mesylate binds to the inactive conformation of BCR-ABL tyrosine kinase, suppressing the Philadelphia chromosome-positive clone in chronic myelogenous leukemia (CML). Clinical studies of imatinib have yielded impressive results in the treatment of all phases of CML. With the higher rates of complete cytogenetic response with imatinib, molecular monitoring of disease has become mandatory in assessing response and determining prognosis. The practical aspects of the treatment of CML with imatinib are discussed. The emergence of imatinib resistance, albeit in a small percentage of patients, has prompted an evaluation of innovative treatment strategies.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. J Clin Oncol. 2003 Apr 15;21(8):1637-47 - PubMed
    1. Cancer. 2004 Jan 1;100(1):116-21 - PubMed
    1. Blood. 2003 Jan 15;101(2):690-8 - PubMed
    1. Haematologica. 2004 Jan;89(1):49-57 - PubMed
    1. Br J Haematol. 2002 Sep;118(3):771-7 - PubMed

MeSH terms

LinkOut - more resources